X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1080) 1080
low-dose aspirin (659) 659
index medicus (595) 595
female (475) 475
male (406) 406
risk factors (330) 330
aged (318) 318
aspirin (315) 315
middle aged (294) 294
prevention (289) 289
molecular-weight heparin (256) 256
anticoagulants - therapeutic use (254) 254
deep-vein thrombosis (229) 229
hematology (222) 222
low-dose warfarin (200) 200
low-dose heparin (197) 197
aspirin - therapeutic use (190) 190
warfarin (179) 179
medicine, general & internal (178) 178
adult (176) 176
anticoagulants (175) 175
platelet aggregation inhibitors - therapeutic use (171) 171
pharmacology & pharmacy (168) 168
peripheral vascular disease (167) 167
risk (163) 163
venous thromboembolism (160) 160
cardiac & cardiovascular systems (159) 159
double-blind (159) 159
thrombosis (148) 148
treatment outcome (148) 148
thromboembolism (144) 144
drug therapy (134) 134
surgery (134) 134
aged, 80 and over (132) 132
aspirin - adverse effects (124) 124
medicine & public health (123) 123
randomized-trial (123) 123
myocardial-infarction (119) 119
care and treatment (114) 114
fibrinolytic agents - therapeutic use (113) 113
therapy (113) 113
oncology (110) 110
thromboembolism - prevention & control (109) 109
anticoagulants - adverse effects (105) 105
gastroenterology & hepatology (105) 105
cancer (104) 104
anticoagulants - administration & dosage (103) 103
nonsteroidal antiinflammatory drugs (103) 103
pulmonary-embolism (103) 103
acute myocardial-infarction (102) 102
mortality (102) 102
risk-factors (102) 102
warfarin - therapeutic use (101) 101
platelet aggregation inhibitors - adverse effects (100) 100
stroke (100) 100
primary prevention (99) 99
aspirin - administration & dosage (94) 94
health aspects (94) 94
randomized controlled trials as topic (93) 93
risk assessment (93) 93
pregnancy (91) 91
secondary prevention (90) 90
unfractionated heparin (89) 89
prophylaxis (87) 87
retrospective studies (87) 87
venous thrombosis - prevention & control (86) 86
dosage and administration (85) 85
heparin (85) 85
heparin - therapeutic use (83) 83
heparin, low-molecular-weight - therapeutic use (83) 83
hemorrhage - chemically induced (82) 82
clopidogrel (81) 81
complications (80) 80
randomized controlled-trial (80) 80
randomized trial (78) 78
thrombosis - prevention & control (78) 78
atrial fibrillation (75) 75
venous thrombosis (75) 75
anticoagulation (74) 74
cardiovascular diseases - prevention & control (73) 73
drug therapy, combination (72) 72
incidence (72) 72
research (72) 72
antiplatelet therapy (71) 71
abridged index medicus (70) 70
postoperative complications - prevention & control (70) 70
clinical trials as topic (69) 69
complications and side effects (69) 69
prospective studies (69) 69
cardiovascular disease (67) 67
neoplasms - complications (66) 66
atrial-fibrillation (65) 65
hemorrhage (65) 65
thrombosis - etiology (65) 65
placebo-controlled trial (64) 64
disease (63) 63
dose-response relationship, drug (63) 63
management (63) 63
total hip-replacement (62) 62
metaanalysis (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1271) 1271
French (21) 21
German (7) 7
Spanish (4) 4
Japanese (2) 2
Russian (2) 2
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced
Journal Article
Journal Article
Journal Article
Food and Chemical Toxicology, ISSN 0278-6915, 03/2018, Volume 113, pp. 19 - 32
Journal Article
American Heart Journal, ISSN 0002-8703, 01/2018, Volume 195, pp. 108 - 114
Journal Article